NAMSNewAmsterdam Pharma Co N.V.BEARISHconviction 1
2026-09-30: Kastelein Johannes Jacob Pieter (Director, Chief Scientific Officer) — scheduled sell (10b5-1 plan) — $1.3M of NAMS (open-market, Form 4, code S) [10b5-1 plan] [vest-and-sell: sold 50,246 sh, all of them vested the same day at no cost to the filer — so $1.3M gross is $1.3M net]
Direction (BULLISH/BEARISH) classifies the event, not the price. It is not a forecast, and no scout's direction has been validated as predictive.
Conviction
Confidence is a heuristic conviction score, not a calibrated probability. On a single filing it is the scout's own 1-5 grade; on a row that rolls several filings together it is their SUM and has no ceiling, so it can read above 5. The stored number is published as it stands — never clamped, never hidden.
Dates
Dates are rendered exactly as filed. A sibyl row leads with the TRADE date the Form 4 reports; a pelosi row shows the member's trade date and the date the disclosure was filed, which are rarely the same day. "Flagged" is the day this feed first published the row.
Backfilled rows
A row marked "already old news when flagged" reached the feed after the fact. It is a record of a filing, not of a timely catch.
Sources
Every row links to the filing it was read from — an SEC Form 4 on EDGAR,
or the disclosure document filed with the House Clerk or the Senate. A row whose source
document this feed cannot link to is left off it.
Free to quote, cite, and reference with attribution to apibeary.com. Informational only — not investment advice. Signals describe observed filings, not recommendations.